Damaris Carriero, NP
Adult Health · New York, NYNPI 1831269794
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 97.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $5,828 and has fallen 90.5% since, to $553 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $267.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$16K
- Madrigal Pharmaceuticals$279
- Ipsen Biopharmaceuticals, Inc$106
- Intra-sana Laboratories$21
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16
What the payments were for
- Consulting fees$2,74017%
- Speaking & faculty fees$8,93056%
- Travel & lodging$3,04419%
- Food & beverage$1,3578%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 49 | $15,649 |
| Madrigal Pharmaceuticals | 8 | $279 |
| Ipsen Biopharmaceuticals, Inc | 1 | $106 |
| Intra-sana Laboratories | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,071 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $78,882 |
| XifaxanRifaximin | 22 | $61,081 |
| VemlidyTenofovir Alafenamide | 35 | $51,843 |
| IsentressRaltegravir Potassium | 24 | $46,747 |
| RezdiffraResmetirom | 11 | $42,762 |
| Isentress HdRaltegravir Potassium | 11 | $22,588 |
| Ursodiol | 96 | $14,359 |
| Entecavir | 50 | $5,818 |
| Tenofovir Disoproxil Fumarate | 39 | $4,049 |
| Mycophenolate Mofetil | 26 | $3,113 |
| Tacrolimus | 21 | $2,479 |
| Valganciclovir Hcl | 11 | $581 |
| Azathioprine | 34 | $425 |
| Famotidine | 29 | $406 |
| Prednisone | 14 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Vemlidy | $15,649 | $130,72571 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $16 | $61,08122 claims |
| Madrigal PharmaceuticalsRezdiffra | $279 | $42,76211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
- Hyo Jin KangNew York$19K
- Monica RicheyNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.